Christopher B. Ehrlich - 14 Feb 2022 Form 4 Insider Report for eFFECTOR Therapeutics, Inc.

Role
Director
Signature
/s/ Michael Byrnes, Attorney-in-Fact for Christopher B. Ehrlich
Issuer symbol
N/A
Transactions as of
14 Feb 2022
Net transactions value
+$13,200
Form type
4
Filing time
22 Feb 2022, 15:59:33 UTC
Previous filing
10 Feb 2022
Next filing
13 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EFTR Common Stock Purchase $8,900 +2,000 +15% $4.45 15,000 14 Feb 2022 Direct F1
transaction EFTR Common Stock Purchase $4,300 +1,000 +6.7% $4.30 16,000 18 Feb 2022 Direct
holding EFTR Common Stock 142,168 14 Feb 2022 By Locust Walk Partners LLC F2
holding EFTR Common Stock 1,034 14 Feb 2022 By Locust Walk Partners LLC F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in two transactions at prices ranging from $4.40 to $4.50. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 Represents shares held directly by the Sponsor, of which Locust Walk Partners LLC ("LWP") is a member. LWP has allocated these shares to the reporting person.
F3 Represents shares held directly by the Sponsor, of which LWP is a member. LWP has allocated these shares to the reporting person's spouse.